RRC ID 41313
Author Suzuki K, Okuno Y, Kawashima N, Muramatsu H, Okuno T, Wang X, Kataoka S, Sekiya Y, Hamada M, Murakami N, Kojima D, Narita K, Narita A, Sakaguchi H, Sakaguchi K, Yoshida N, Nishio N, Hama A, Takahashi Y, Kudo K, Kato K, Kojima S.
Title MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
Journal J. Clin. Oncol.
Abstract PURPOSE:Acute lymphoblastic leukemia (ALL) makes up a significant proportion of all pediatric cancers, and relapsed ALL is a leading cause of cancer-associated deaths in children. Identification of risk factors and druggable molecular targets in ALL can lead to a better stratification of treatments and subsequent improvement in prognosis.
PATIENTS AND METHODS:We enrolled 59 children with relapsed or primary refractory ALL who were treated in our institutions. We primarily performed RNA sequencing (RNA-seq) using patients' leukemic cells to comprehensively detect gene fusions and analyze gene expression profiles. On the basis of results obtained by RNA-seq, we performed genetic validation, functional analysis, and in vitro drug sensitivity testing using patients' samples and an exogenous expression model.
RESULTS:We identified a total of 26 gene fusions in 22 patients by RNA-seq. Among these, 19 were nonrandom gene fusions already described in ALL, and four of the remaining seven involved identical combination of MEF2D and BCL9. All MEF2D-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9. Exogenous expression of MEF2D-BCL9 in a B-cell precursor ALL cell line promoted cell growth, increased HDAC9 expression, and induced resistance to dexamethasone. Using a primary culture of leukemic blasts from a patient, we identified several molecular targeted drugs that conferred inhibitory effects in vitro.
CONCLUSION:A novel MEF2D-BCL9 fusion we identified characterizes a novel subset of pediatric ALL, predicts poor prognosis, and may be a candidate for novel molecular targeting.
Volume 34(28)
Pages 3451-9
Published 2016-10-1
DOI 10.1200/JCO.2016.66.5547
PII JCO.2016.66.5547
PMID 27507882
MeSH Adolescent Bortezomib / pharmacology Cell Line, Tumor Child Dexamethasone / pharmacology Drug Screening Assays, Antitumor HEK293 Cells Histone Deacetylases / biosynthesis Histone Deacetylases / genetics Humans Hydroxamic Acids / pharmacology Infant MEF2 Transcription Factors / genetics Molecular Targeted Therapy Neoplasm Proteins / genetics* Oncogene Proteins, Fusion / genetics* Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics* Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology RNA, Neoplasm / genetics Repressor Proteins / biosynthesis Repressor Proteins / genetics Sequence Analysis, RNA Tumor Cells, Cultured
IF 26.36
Times Cited 3
WOS Category ONCOLOGY
Resource
DNA material CSIV-CMV-MCS-IRES2-Venus (RDB08257) pCAG-HIVgp (RDB04394) pCMV-VSV-G-RSV-Rev (RDB04393).